Business Standard

Serum Institute likely to launch cervical cancer vaccine in India in Nov

Country now depends on foreign companies and Serum's product is likely to bring down prices.

Photo: Abhishek Waghmare
Premium

Photo: Abhishek Waghmare

Sohini Das Mumbai
An India-made cervical cancer vaccine would be available by November when Serum Institute of India (SII) launches its Quadrivalent Human Papillomavirus (qHPV) inoculation.

According to sources, the company is stocking the vaccine as it awaits a clearance from the country's drug regulator. India now has HPV vaccines made by foreign manufacturers: Gardasil, manufactured by Merck, and Cervarix by Glaxo Smithkline. SII’s entry into this space is expected to bring down the prices. HPV vaccines are now available in the range of Rs 2,000-3,000 per dose.

SII will soon seek a marketing authorisation for the vaccine from the regulator. However, since

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in